The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats

Pharmacological Research

Volumn 43, Issue 3, 2001, Pages 211-218

  Saad, Sherif Y ^a   Najjar, Tawfeeg A ^a   Al Rikabi, Ammar C ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cardiotoxicity; Deferoxamine; Doxorubicin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE MB; CREATININE; DEFEROXAMINE; DOXORUBICIN; GLUTATHIONE; LACTATE DEHYDROGENASE; MALONALDEHYDE;

ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; CYTOPATHOLOGY; DOSE CALCULATION; DOSE RESPONSE; DRUG MECHANISM; HISTOPATHOLOGY; IRON CHELATION; KIDNEY PARENCHYMA; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; UREA NITROGEN BLOOD LEVEL;

EID: 0034957066     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2000.0769     Document Type: Article

References (52)

1. Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture
2. Induction of antioxidants by adriamycin in mouse heart
3. The impairment of essential fatty acid metabolism as a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes
4. The role of iron and iron chelators in anthracycline cardiotoxicity
5. Anthracycline cardiotoxicity: In vivo and in vitro effects on biochemical parameters and heart ultrastructure of the rat
6. Release of iron from ferritin by cardiotoxic anthracycline antibiotics
7. Cytoprotective agents for anthracyclines
8. Glutamine protects against doxorubicin-induced cardiotoxicity
9. L-carnitine attenuates doxorubicin-induced lipid peroxidation in rats
10. Anthracycline toxicity is potential by iron and inhibited by deferoxamine: Studies in rat heart cells in culture
11. Role of iron in the potentiation of anthracycline cardiotixicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction
12. Prevention of anthracycline cardiotoxicity by iron chelation
13. Ability of the orally effective iron chelators dimethyl- and diethylhydroxypyride-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells
14. The quantitation of albumin based on dye linear binding capacity
15. On the colorimetric determination of creatinine by Jaffe reaction
16. Reduced nicotinamide adenine dinucleotide for emergency blood urea estimation
17. Optimization of methods for aspartate aminotransferase and alanine aminotransferase
18. Tissue sulfahydryl groups
19. Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction
20. Paradoxicol inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity
21. The effects of alpha-tocopheral on the toxicity, disposition, and metabolism of adriamycin in mice
22. Indication of reduced doxorubicin-induced cardiac toxicity by additional treatment with antioxidant substances
23. Ascorbic acid in adriamycin toxicity
24. Protection by salvianolic acid against adriamycin toxicity on rat heart mitochondria
25. 10
26. 10 on ECG changes induced by doxorubicin (adriamycin)
27. Enhanced resistance of adriamycin-treated MCR-5 lung fibroblasts by increased intracellular glutathione peroxidase and extracellular antioxidants
28. Prevention of hydroxyl radical formation: A critical concept for improving cardioplegia. Protective effect of deferoxamine
29. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity
30. Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine
31. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality
32. In vivo prevention of adriamycin cardiotoxicity by cyclosporin A or FK506
33. Curcumin attenuation of acute adriamycin myocardial toxicity in rats
34. Experimental focal segmental glomerulosclerosis in mice
35. A possible role for membrane lipid peroxidation in anthracyclin nephrotoxicity
36. Hepatotoxicity of mitoxantrone and doxorubicin
37. Inhibitory effect of dioxopiperazine compounds on malondialdehyde formation induced by doxorubicin in rat liver mitochondria in vitro
38. Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat
39. Effect of captopril on doxorubicin-induced nephrotoxicity in normal rats
40. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants
41. A canine model of heart failure by intracoronary adriamycin injection: Hemodynamic and energetic results
42. Iron availability and free radical induced injury in isolated ischaemic/reperfusion rat heart
43. The effect of desferal on rat heart mitochondrial function, iron content and Xanthine dehydrogenase/oxidase conversion during ischemia-reperfusion
44. NADPH- and adriamycin-dependent microsomal release of iron and lipid peroxidation
45. Deferoxamine-induced iron mobilization and redistribution of myocardial iron in cultured rat heart cells: Studies of the chelatable iron pool by electron microscopy and mossbauer spectroscopy
46. Deferoxamine (desferrioxamine). New toxicities of an old drug
47. Chelation therapy in cardiovascular disease: Ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane
48. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats
49. Doxorubicin pharmacokinetics is altered differently by the cytoprotective agents amifostine or cardioxane (ICRF-187)
50. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy
51. Persistent effects of doxorubicin on cardiac gene expression
52. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: Role of inhibition of ceramide generation